Background. Perinatal Hepatitis B Virus (HBV) transmission results in chronic disease in 90% of infected infants. Immunoprophylaxis reduces perinatal HBV infections by 95%. For women with viral loads >200,000 IU/mL, antiviral therapy during pregnancy is recommended to further reduce perinatal transmission. We sought to characterize antiviral therapy use in Hepatitis B-infected pregnant women.
Methods. The Centers for Disease Control and Prevention (CDC) provided auxiliary funding for five Perinatal Hepatitis B Prevention Programs. We analyzed data collected retrospectively from Hepatitis B-infected pregnant women in Georgia, Michigan, New York City, Philadelphia, and Wisconsin identified as having live births during April 2016-December 2017. We assessed maternal antiviral therapy use during pregnancy; HBV DNA levels included in our analysis were from the last result available prior to delivery for each woman.
Results. We identified 3,971 pregnant women with HBV infection; of these, 803 (20.2%) had information regarding prescription of antiviral therapy during pregnancy. HBV DNA levels were known for 1,907 women, of whom 9.1% (n = 173) had HBV DNA >200,000 IU/mL nearest delivery. Antiviral therapy was prescribed for 26.5% (n = 213) of women with information. Antiviral therapy was more commonly prescribed for women aged <30 years vs. ≥30 years (32.0% vs. 23.1%, P = 0.0069), Asian/Pacific Island race vs. White or Black (42.7% vs. 2.8% and 6.2%, respectively, P < 0.0001), and those whose HBV was monitored by a gastroenterologist/hepatologist vs. maternal fetal medicine or infectious disease specialist (55.1% vs. 10.3% and 36.4%, respectively, P < 0.0001). Tenofovir was prescribed for 92.9% of women prescribed antiviral therapy; lamivudine was prescribed for 3.8%.
Conclusion. Antiviral therapy was prescribed for one-fourth of Hepatitis B-infected women with information and was more commonly prescribed for women who were younger, Asian/Pacific Island race, and who received Hepatitis B care from a gastroenterologist/hepatologist. Although these are preliminary findings and data collection is ongoing, opportunities may exist to improve guideline-concordant antiviral therapy use among Hepatitis B-infected pregnant women.
NOTE: Prevention of perinatal HBV transmission is an off-label use of antiviral therapy.
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This abstract has been withdrawn at the author's request. Background. Hepatitis C is a chronic life-threatening disease which is curable. However, ~60% of Hep C-infected individuals are unaware of their infection status. The majority of Hep C has been documented in baby boomers (born 1946 -1965 PMID:22895429) .
S650 • OFID 2018:5 (Suppl 1) • Poster Abstracts

Prevalence of Hepatitis C in Adults Presenting to Emergency Departments in a Large Hospital System in Texas
Methods. Prospective case study of adults presenting to the Emergency Departments (EDs) of a large is not for profit hospital system in the Houston, Texas area. Adults presenting between March 2013 and October 2016 were eligible for testing for antibody to Hep C (Gilead).
Results. Over the 3.5 years study, 8,159 patients presenting to nine participating EDs in the Houston, Texas region were screened for Hep C. There were 744 (10.0%) individuals found positive. Prevalence of Hep C by testing ED ranged from 4.0 to 13.7% (P < 0.001) and males (11.8%) were significantly (P < 0.001) more frequently positive than females (6.6%). When parsed by age categories; individuals born before 1946 (3.8% Hep C positive) had a significantly lower (P < 0.001) prevalence of Hep C than cohorts born between 1946 and 1965 (9.6%+) or after 1965 (9.2%+).
Conclusion. Hep C is prevalent in adult patients presenting to EDs in the Houston, Texas region. The 10% Hep C positivity rate is similar to that found (11.6%) in another Gulf state, Alabama (PMID: 26611776). Our findings differ in that prevalence in individuals born after 1965 was as high as that for baby boomers.
Disclosures Background. Huge efforts are being made to screen high-risk populations for Hepatitis C virus (HCV) infection, however linkage to care (LTC) rates remain low. The aim of this study was to assess the factors affecting LTC among HCV positives in a major tertiary academic medical center in eastern New York.
Methods. A retrospective chart review was performed on all patients with ICD-9 or 10 diagnostic codes for HCV positive antibody over a period of 2 years (2016) (2017) at Stony Brook Medicine. Data were collected for HCV RNA, LTC, demographics, type of insurance, employment status, psychiatric diagnosis, comorbidities, HIV or HBV coinfections, substance use disorder, and level of fibrosis. Univariate and multivariate analyses were performed to find associated factors with LTC.
Results. A total of 600 cases (62.6% male; 74% White; median age: 59 years) had a positive HCV antibody, 264 (44.4%) had a positive follow-up HCV RNA test and 138 (52.2%) were LTC. The average time for LTC was 1.5 months (50 days; interquartile range 21-121). In the univariate analysis, the following factors were significantly associated with LTC: older age (OR 1.022), having medicaid (OR 0.421), people who inject drugs (PWID) (OR 0.216), cocaine and marijuana use (OR 0.457), polysubstance use (OR 0.311), having a primary care provider (OR 2.290) and being a baby boomer (OR 1.718). The vast majority of patients came from three zip codes within south central Suffolk County, coinciding with the highest prevalence of heroin use.
Conclusion. In this population insurance type, younger age and substance use (injection drugs, marijuana, cocaine, polysubstance) were associated with lower odds of LTC. Having a primary care provider and being a baby boomer were the only two independent risk factors associated with increased odds of LTC. Due to an increased number of HCV cases in younger populations, particularly PWID, further outreach efforts are urgently needed to spread HCV screening awareness and increase testing in high prevalence areas.
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